Exact Sciences (EXAS) Misses Q1 EPS by 10c

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.71), $0.10 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $347.8 million versus the consensus estimate of $350.39 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• ICON plc (ICLR) PT Raised to $150 at BofA Securities
• Barclays Downgrades Brown Forman (BF-B) to Equalweight